← Back
Data updated: Mar 10, 2026
FORMYCON AG
OphthalmologyOncology
FORMYCON AG is a biotechnology company focused on Ophthalmology, Oncology.
2024
Since
2
Drugs
-
Trials
3
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
NUFYMCO 2025-12-18
Type 2 - New Active Ingredient
AHZANTIVE 2025-04-17
Supplement
AHZANTIVE 2024-06-28
Type 3 - New Dosage Form
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Ophthalmology 62%
1 drugs Phase 1: 2
Oncology 38%
0 drugs Phase 3: 1 Phase 1: 1
Pipeline Strength Pro
Loading...